Clinical Trial Update: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates the Phase 1/2 study evaluating TQB3912 tablets with fulvestrant, with or without TQB3616, for locally advanced or metastatic H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• TQB3616
• TQB3912

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED